nike dunks discount
nike sb skunk
Pfizer released its checkbook again. Having spent last year, 67 billion

dollars to afford his compatriot Wyeth, the pharmaceutical giant announced the

yesterday the purchase of King Pharmaceuticals, a group of Bristol (Tennessee) present in

prescription drugs, medical devices and animal health. The amount of

transaction amounts to $ 3.6 billion (2.6 billion euros) in cash or

14.25 dollars per share.

If the world's number one industry agrees to pay a premium of approximately 40% over the course of

King closed Monday, is that he desperately needed to stem the fall in sales.

Pfizer is in danger of losing a quarter of its sales next year, when

Its flagship product, Lipitor (Tahor in France) will lose patent protection and may

be legally copied. However, this cholesterol is the top-selling drug in the world

with $ 11.4 billion in sales last year.
$ 200 million savings

For his part, King, which employs 2,600 people, has made 1.8 billion dollars in sales

in 2009 and reached 555 million operating surplus. The laboratory is specialized
Nike Air Max sale
painkillers in a growing market with products that, according to Pfizer, have

the subject of some 320 million prescriptions last year in the United States.

Pfizer, which already sells Lyrica and Celebrex, and puts his hand on Avinza, and Flector

Embed. But beyond the already-marketed drugs, the project portfolio

King of interest to the group led by Jeff Kindler. It will enable Pfizer to replenish

its "pipeline" amputated in 2010 for three projects, in particular the use of Celebrex

cons gout. The drug was yet in the final phase of human trials before

placed on the market.

The operation should improve earnings by 2 cents per share from Pfizer in 2011 and 2012

March-April cents per year between 2013 and 2015. The group also expects at least 200

millions of dollars in savings. The transaction must be fastened at the end of March

2011.
Nike Dunks Low
Nike Dunks High
Nike Dunks Mid
Nike Dunks Women